This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Black, P. C. Articles by Dinney, C. P. Search for Related Content PubMed PubMed Citation Articles by Black, P. C. Articles by Dinney, C. P.

Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer

Peter C. Black, Gordon A. Brown, Colin P. Dinney

From the Department of Urology, the University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Colin P. Dinney, MD, Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX 77030 e-mail: cdinney{at}mdanderson.org

Multiple molecular markers have been described for use in bladder cancer patients. Some of these have been studied more extensively than others, and it is difficult for the clinician to maintain a perspective over the myriad findings that have been made. We have reviewed a selection of markers used for surveillance with an emphasis on clinical utility. The best studied markers and those with the most promising preliminary results were selected. Only studies that included surveillance for recurrence in patients with a history of bladder cancer were considered. Each marker is briefly described and its performance in monitoring bladder cancer patients is summarized. Several promising markers are available, although only four have obtained US Food and Drug Administration approval. The clinical applications that have been studied include replacement or reduction in the number of cystoscopies performed in the surveillance of bladder cancer patients, substitution for or complementary use with urinary cytology in the same setting, predicting disease recurrence and progression, and predicting and monitoring treatment response. None of the markers have been proved sensitive and specific enough to replace cystoscopy. Others, such as nuclear matrix protein 22 (NMP22) and UroVysion, appear to have some utility when used to complement or replace cytology. The other applications have not been adequately studied for any given marker. While multiple molecular markers exist for bladder cancer, their full clinical utility will not be realized until more multicenter prospective trials are conducted to verify their efficacy and safety in the monitoring of patients with superficial bladder cancer.

Supported by National Institutes of Health (NIH) GU Bladder SPORE CA91846, an American Urological Association Foundation grant, NIH T32 Training Grant No. CA079449, and the Cancer Center Core Grant No. CA16672.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				B. R. Knab, J. K. Salama, A. Solanki, K. M. Stenson, E. E. Cohen, M. E. Witt, D. J. Haraf, and E. E. Vokes Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma Ann. Onc., September 1, 2008; 19(9): 1650 - 1654. [Abstract] [Full Text] [PDF]

				P. K. RAO and J. S. JONES How to evaluate 'dipstick hematuria': What to do before you refer Cleveland Clinic Journal of Medicine, March 1, 2008; 75(3): 227 - 233. [Abstract] [Full Text] [PDF]

				D. F. Bajorin, R. J. Motzer, and G. J. Bosl Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481. [Full Text] [PDF]